Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy
✍ Scribed by Florence Legrand-Abravanel; Philippe Colson; Hélène Leguillou-Guillemette; Laurent Alric; Isabelle Ravaux; Françoise Lunel-Fabiani; Magali Bouviers-Alias; Pascale Trimoulet; Marie Laure Chaix; Christophe Hézode; Juliette Foucher; Hélène Fontaine; Anne-Marie Roque-Afonso; Michèle Gassin; Evelyne Schvoerer; Catherine Gaudy; Bruno Roche; Michel Doffoël; Louis D'Alteroche; Sophie Vallet; Yazid Baazia; Bruno Pozzetto; Vincent Thibault; Jean-Baptiste Nousbaum; Dominique Roulot; Henry Coppere; Thierry Poinard; Christopher Payan; Jacques Izopet
- Book ID
- 102381958
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 89 KB
- Volume
- 81
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The hepatitis C virus genotype is considered to be the most important baseline predictor of a sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The influence of the subtype on the sustained virological response was investigated in patients infected with genotypes 1, 4, 5, or 6. This study was done on 597 patients with chronic hepatitis C who were given pegylated interferon and ribavirin for 48 weeks. The overall rate of sustained virological response in the 597 patients was 37.8%. Univariate analysis indicated that the sustained virological response of patients infected with subtype 1b (39%) tended to be higher than that of patients infected with subtype 1a (30.6%; P = 0.06) and it was similar to those patients infected with subtypes 4a (51.3%; P = 0.12) or 4d (51.7%; P = 0.16). Multivariate analysis indicated that five factors were independently associated with sustained virological response: the age (OR 0.97; 95% CI = 0.95–0.99), absence of cirrhosis (OR: 2.92; 95% CI = 1.7–5.0; P < 0.01), absence of HIV co‐infection (OR: 2.08; 95% CI = 1.2–3.5; P < 0.01), low baseline plasma HCV RNA concentration (OR: 1.74; 95% CI = 1.2–2.6; P < 0.01), and the subtype 1b (OR: 1.61; 95% CI = 1.0–2.5; P = 0.04) or subtypes 4a and 4d (OR: 2.03; 95% CI = 1.1–3.8; P = 0.03). In conclusion, among difficult‐to‐treat genotypes, the subtype 1a is associated with a lower response to anti‐HCV therapy than subtypes 1b, 4a, and 4d. J. Med. Virol. 81:2029–2035, 2009. © 2009 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract New factors that influence the viral response in HCV non‐genotype 2/3 patients must be identified in order to optimize anti‐HCV treatment. This multicenter prospective study evaluates the influence of HCV variability and pharmacological parameters on the virological response of these pa
## Abstract The aim of the study was to identify a predictive marker for the virological response in hepatitis C virus 1b (HCV‐1b)‐infected patients treated with pegylated interferon plus ribavirin therapy. A total of 139 patients with chronic hepatitis C who received therapy for 48 weeks were enro